

=> fil reg; d stat que l12  
 FILE 'REGISTRY' ENTERED AT 14:35:41 ON 13 SEP 2004  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 10 SEP 2004 HIGHEST RN 742663-39-4  
 DICTIONARY FILE UPDATES: 10 SEP 2004 HIGHEST RN 742663-39-4



TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
 information enter HELP PROP at an arrow prompt in the file or refer  
 to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L9 STR



G1 @28



Ak~Cy  
 @32 33

Ak @34

VAR G1=10/20  
 VAR G2=H/X/34/CY/32  
 REP G3=(0-3) CH2  
 VAR G5=32/CY  
 VPA 28-1/2/5/6 U

NODE ATTRIBUTES:

NSPEC	IS	RC	AT	12
NSPEC	IS	RC	AT	13
NSPEC	IS	RC	AT	15
NSPEC	IS	RC	AT	16
NSPEC	IS	RC	AT	18
NSPEC	IS	RC	AT	21
NSPEC	IS	RC	AT	22
NSPEC	IS	RC	AT	24
NSPEC	IS	RC	AT	25
NSPEC	IS	RC	AT	27
CONNECT	IS	E2	RC	AT 32

CONNECT IS E1 RC AT 34  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 39

STEREO ATTRIBUTES: NONE  
L12 217 SEA FILE=REGISTRY SSS FUL L9

100.0% PROCESSED 165291 ITERATIONS 217 ANSWERS  
SEARCH TIME: 00.00.12

=> fil capl uspatf biosis toxcenter; s l12  
FILE 'CAPLUS' ENTERED AT 14:35:56 ON 13 SEP 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:35:56 ON 13 SEP 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 14:35:56 ON 13 SEP 2004  
Copyright (c) 2004 The Thomson Corporation.

FILE 'TOXCENTER' ENTERED AT 14:35:56 ON 13 SEP 2004  
COPYRIGHT (C) 2004 ACS

L15 21 L12

=> dup rem l15  
PROCESSING COMPLETED FOR L15  
L16 13 DUP REM L15 (8 DUPLICATES REMOVED)  
ANSWERS '1-9' FROM FILE CAPLUS  
ANSWERS '10-11' FROM FILE USPATFULL  
ANSWERS '12-13' FROM FILE BIOSIS

=> d ibib ed abs hitstr 1-11; d iall 12-13

L16 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1  
ACCESSION NUMBER: 2002:575744 CAPLUS  
DOCUMENT NUMBER: 137:135069  
TITLE: Method for reducing or preventing the establishment,  
growth or metastasis of cancer by administering indole  
peptidomimetics PAR-1 antagonist and optionally PAR-2  
antagonists  
INVENTOR(S): D'Andrea, Michael; Derian, Claudia; Woodrow, Hal Brent  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S.  
Ser. No. 603,231.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2002103138	A1	20020801	US 2001-865824	20010525
US 2003224999	A1	20031204	US 2003-403542	20030331
PRIORITY APPLN. INFO.:			US 1999-141550P	P 19990629
			US 2000-603231	A2 20000626

OTHER SOURCE(S): MARPAT 137:135069

ED Entered STN: 02 Aug 2002

AB The authors have discovered a method of modifying the tumor cell microenvironment to reduce or prevent the establishment, growth or metastasis of malignant cells comprising administering to a patient having malignant cells a pharmaceutically effective amt. of a PAR-1 (proteinase-activated receptor 1) inhibitor and optionally a PAR-2 (proteinase-activated receptor 2) inhibitor to prevent or reduce activation of normal cells within the tumor microenvironment. This method also has the effect in some patients of modulating the immune system to facilitate a more efficient immune response to malignant cells and maybe coupled with cytokine therapy and T-cell therapy to enhance the patient's immune response to the malignant cells.

IT **252889-86-4P**, L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- **252889-87-5P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- **252889-88-6P**, Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- **252889-89-7P**, L-Methioninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)- **316149-47-0P**, L-Argininamide, O-methyl-N-[[[1-[(4-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- **316149-49-2P**, L-Argininamide, N-[[[3-[(cyclopentylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- **316149-51-6P**, L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(3-phenylpropyl)- **316149-53-8P**, L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(3-phenylpropyl)- **316149-55-0P**, L-Argininamide, N-[[[1-[(3-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- **316149-57-2P**, L-Argininamide, N-[[[1-[(2-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- **316149-59-4P**, L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(cyclohexylmethyl)- **316149-61-8P**, L-Argininamide, O-methyl-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(cyclohexylmethyl)- **316149-63-0P**, L-Argininamide, N-[[[1-[(4-methoxycarbonyl)phenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(cyclohexylmethyl)- **316149-65-2P**, L-Argininamide, O-methyl-N-[[[3-(1-pyrrolidinylmethyl)-1-[(4-(trifluoromethoxy)phenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(cyclohexylmethyl)- **316149-67-4P**, L-Argininamide, O-methyl-N-[[[1-[(4-methylsulfonyl)phenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- **316149-69-6P**, L-Argininamide, N-[[[1-[(4-cyanophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- **316149-71-0P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- **316149-73-2P**, L-Argininamide,

O-methyl-N-[[[1-(2-naphthalenylmethyl)-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- **316149-75-4P**,  
L-Argininamide, N-[[[1-[(3-methoxyphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)-  
**316149-77-6P**, L-Argininamide, O-methyl-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- **316149-79-8P**,  
L-Argininamide, O-methyl-N-[[[3-(1-pyrrolidinylmethyl)-1-[[4-(trifluoromethyl)phenyl]methyl]-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- **316149-81-2P**, L-Argininamide,  
N-[[[1-[(4-chlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)-  
**316149-83-4P**, L-Argininamide, N-[[[1-[(4-methoxyphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- **316149-85-6P**, L-Argininamide,  
N-[[[1-[(3,4-difluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)-  
**316149-87-8P**, L-Argininamide, O-methyl-N-[[[1-(phenylmethyl)-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- **316149-89-0P**, L-Argininamide,  
N-[[[1-[(4-iodophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)-  
**316149-91-4P**, L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(4-pyridinyl)-L-alanyl-N-(phenylmethyl)- **316149-93-6P**, L-Argininamide,  
3-cyclohexyl-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-alanyl-N-(phenylmethyl)- **316149-95-8P**,  
L-Argininamide, 4-fluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- **316149-97-0P**, Benzenebutanamide,  
N-[(1S)-4-[(aminoiminomethyl)amino]-1-[(phenylmethyl)amino]carbonyl]butyl]-.alpha.-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- **316149-99-2P**,  
L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(2-thienyl)-L-alanyl-N-(phenylmethyl)-  
**316150-01-3P**, L-Argininamide, (2S)-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-2-phenylglycyl-N-(phenylmethyl)- **316150-03-5P**, 2,3(1H)-Isoquinolinedicarboxamide,  
N3-[(1S)-4-[(aminoiminomethyl)amino]-1-[(phenylmethyl)amino]carbonyl]butyl]-N2-[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]-3,4-dihydro-, (3S)- **316150-05-7P**, L-Argininamide,  
N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(3-pyridinyl)-L-alanyl-N-(phenylmethyl)-  
**316150-07-9P**, L-Argininamide, N-[[[3-[[3-(dimethylamino)propyl]methylamino]methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)-  
**316150-09-1P**, L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-[[3-(1-pyrrolidinyl)propyl]amino]methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- **316150-11-5P**, L-Argininamide,  
N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-2-propenyl-L-tyrosyl-N-(phenylmethyl)-  
**316150-13-7P**, L-Argininamide, 4-amino-N-[[[3-[(diethylamino)methyl]-1-[(2-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- **316150-15-9P**,  
L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-(phenylmethyl)-  
**316150-17-1P**, L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(1-naphthalenyl)-L-alanyl-N-(phenylmethyl)- **316150-19-3P**, L-Argininamide,  
N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(2-naphthalenyl)-L-alanyl-N-(phenylmethyl)-  
**316150-21-7P**, L-Argininamide, 3-[1,1'-biphenyl]-4-yl-N-[[[1-[(2-



methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-alanyl-N-(phenylmethyl)- **316150-23-9P**, L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(4-morpholinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- **316150-25-1P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[(dipropylamino)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- **316150-27-3P**, L-Argininamide, O-ethyl-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- **316150-29-5P**, L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[(3-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-(1-methylethyl)-L-tyrosyl-N-(phenylmethyl)- **316150-31-9P**, L-Argininamide, N-[[[3-(1-azetidinylmethyl)-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- **316150-33-1P**, L-Argininamide, N-[[[3-[(cyclopropylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- **316150-36-4P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(phenylmethyl)- **316150-38-6P**, L-Argininamide, 4-chloro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- **316150-40-0P**, L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-4-nitro-L-phenylalanyl-N-(phenylmethyl)- **316150-42-2P**, L-Argininamide, 2,3,4,5,6-pentafluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- **316150-44-4P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-2-fluoro-L-phenylalanyl-N-(phenylmethyl)- **316150-46-6P**, L-Argininamide, 4-cyano-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- **316150-48-8P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(4-thiazolyl)-L-alanyl-N-(phenylmethyl)- **316150-50-2P**, L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(trifluoromethyl)-L-phenylalanyl-N-(phenylmethyl)- **316150-52-4P**, L-Argininamide, N-[[[1-[(2-chlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- **316150-54-6P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-.beta.-phenyl-L-phenylalanyl-N-(phenylmethyl)- **316150-56-8P**, L-Argininamide, 3,4-difluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-phenylethyl)- **316150-58-0P**, L-Argininamide, N-[[[3-[(dibutylamino)methyl]-1-[(2-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- **316150-60-4P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(4-fluorophenyl)methyl]- **316150-62-6P**, L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(diphenylmethyl)- **316150-64-8P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(4-methoxyphenyl)methyl]- **316150-66-0P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(4-pyridinylmethyl)- **316150-68-2P**, L-Argininamide, 4-bromo-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- **316150-70-6P**, L-Argininamide, 3,4-difluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-

indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(2-chlorophenyl)ethyl]-  
**316150-72-8P**, L-Argininamide, 3,4-difluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(2-methoxyphenyl)ethyl]-  
**316150-75-1P**, L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-  
**316150-77-3P**, L-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N6-(1-methylethyl)-N-(phenylmethyl)-  
**316150-79-5P**, L-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-N6-(3-pyridinylcarbonyl)-  
**316150-81-9P**, D-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-  
**316150-83-1P**, D-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-  
**316150-85-3P**, D-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N6-acetyl-N-(phenylmethyl)-  
**316150-87-5P**, D-Histidinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-  
**316150-89-7P**, L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-octyl-  
**316150-91-1P**, L-Argininamide, N-[[[1-(cyclohexylmethyl)-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-  
**316150-93-3P**, L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-(3-phenylpropyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-  
**316150-95-5P**, L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[2-(4-fluorophenyl)ethyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-  
**316150-97-7P**, L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N5-(aminocarbonyl)-N-(phenylmethyl)-  
**316150-98-8P**, Benzenepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl-4-chloro-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)-  
**316151-00-5P**, L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-3-amino-N-(phenylmethyl)-  
**316151-02-7P**, L-Phenylalaninamide, N2-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-arginyl-3,4-difluoro-N-(phenylmethyl)-  
**316151-04-9P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(5-aminopentyl)-  
**316151-06-1P**, L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-furanylmethyl)-  
**316151-08-3P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(2R)-2-phenylpropyl]-  
**316151-10-7P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,5-difluoro-D-phenylalanyl-N-(phenylmethyl)-  
**316151-12-9P**, L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-4-iodo-L-phenylalanyl-N-(phenylmethyl)-  
**316151-14-1P**, L-Argininamide, 2-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)-  
**316151-16-3P**, L-Argininamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]-1H-indol-6-yl]amino]carbonyl]-L-

phenylalanyl-N-(phenylmethyl)- **316151-18-5P**, L-Argininamide,  
N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[(4-oxo-1-piperidinyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(phenylmethyl)-  
**316151-20-9P**, L-Argininamide, 3-fluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-naphthalenyl)- **316151-22-1P**,  
L-Argininamide, N-[[[3-[(3-(dimethylamino)-1-pyrrolidinyl)methyl]-1-[(2-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-D-phenylalanyl-N-(phenylmethyl)- **316151-25-4P**, L-Argininamide,  
N-[[[1-[(3,5-dichloro-4-pyridinyl)methyl]-3-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(phenylmethyl)- **316151-27-6P**, L-Argininamide,  
N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-[[4-(aminosulfonyl)phenyl)methyl]- **316151-30-1P**, L-Ornithinamide,  
N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5-acetyl-N-(phenylmethyl)-  
**316151-32-3P**, L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5-(1-iminoethyl)-N-(phenylmethyl)- **316151-34-5P**,  
L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- **316151-36-7P**,  
L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[(methyl-2-propenylamino)methyl]-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- **316151-38-9P**,  
L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(4-pyridinylmethyl)- **316151-40-3P**,  
L-Ornithinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[(2-chlorophenyl)methyl]- **316151-42-5P**, L-Ornithinamide,  
N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5,N5-dimethyl-N-(phenylmethyl)- **316151-44-7P**, L-Alaninamide,  
N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-3-amino-N-(phenylmethyl)-  
**316151-47-0P**, L-Glutamamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N1-(phenylmethyl)- **316151-49-2P**, L-Methioninamide,  
N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-  
**316151-51-6P**, L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-3-(4-pyridinyl)- **316151-53-8P**,  
L-Phenylalalaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-4-amino-N-(phenylmethyl)- **316151-55-0P**,  
L-Argininamide, 1-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-prolyl-N-(phenylmethyl)- **316151-59-4P**, L-Ornithinamide,  
N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[2-(4-pyridinyl)ethyl]-  
**316151-60-7P**, L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-ethyl-N-(4-pyridinylmethyl)- **316151-62-9P**,  
L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-methyl-N-(phenylmethyl)- **316151-64-1P**,  
L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(3,4-dichlorophenyl)methyl]- **316151-66-3P**,

L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-thienylmethyl)- **316151-69-6P**, Benzenepropanamide, N-[(1S)-4-amino-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- **316151-71-0P**, Benzenepropanamide, N-[(1S)-4-amino-1-(1-piperidinylcarbonyl)butyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- **316151-73-2P**, L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(3-pyridinylmethyl)- **316151-75-4P**, L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-pyridinylmethyl)- **316151-77-6P**, Benzenepropanamide, .alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-N-[(1S)-3-[(1-iminoethyl)amino]-1-[(phenylmethyl)amino]carbonyl]propyl]-, (.alpha.S)- **316151-79-8P**, L-Ornithinamide, 4-chloro-N-[[[3-[(cyclopentylmethylamino)methyl]-1-[(2,6-dichlorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(2-chlorophenyl)ethyl]- **316151-81-2P**, L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[[2-(dimethylamino)ethyl]amino]methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- **316151-83-4P**, L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[[3-(dimethylamino)propyl]amino]methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- **316151-85-6P**, L-Ornithinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[[1,3-dioxolan-2-ylmethyl]methylamino]methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- **316151-87-8P**, L-Ornithinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(4-morpholinyl)ethyl]- **316151-89-0P**, L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[2-(1-methyl-1H-imidazol-4-yl)ethyl]- **316151-91-4P**, L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-cyclopentyl- **316151-92-5P**, L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[2-(dimethylamino)ethyl]- **316151-94-7P**, L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-phenyl- **316151-96-9P**, Benzenebutanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- **316151-98-1P**, 2-Naphthalenepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- **316152-00-8P**, 3-Pyridinepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- **316152-02-0P**, 2-Thiophenepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- **316152-04-2P**, 4-Thiazolepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- **316152-06-4P**, L-Phenylalaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-

pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- **316152-08-6P**, L-Histidinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- **316152-10-0P**, L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- **316152-11-1P**, L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- **316152-13-3P**, L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-thiazolyl)- **316152-15-5P**, L-Phenylalaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-fluoro- **316152-17-7P**, L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-[(1-iminoethyl)amino]ethyl]-3-(4-pyridinyl)- **316152-19-9P**, 2,5,8,11-Tetraazatridecanamide, N-[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]-3-[(3,4-difluorophenyl)methyl]-12-imino-6-[2-[(1-iminoethyl)amino]ethyl]-4,7-dioxo-, (3S,6S)- **316152-20-2P**, Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- **316152-21-3P**, Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(1H-imidazol-1-yl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- **316152-23-5P**, 1-Piperidinecarboxylic acid, 4-[[[(2S)-4-amino-2-[[[(2S)-2-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3-(3,4-difluorophenyl)-1-oxopropyl]amino]-1-oxobutyl]amino]-, ethyl ester **316152-25-7P**, L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(4-pyridinyl)- **316152-28-0P**, Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(2-aminoethyl)- **316152-29-1P**, L-Valinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- **316152-31-5P**, L-Cysteinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-S-ethyl- **316152-33-7P**, L-Serinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)- **316152-35-9P**, L-Cysteinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-S-(triphenylmethyl)- **316152-37-1P**, D-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- **316152-39-3P**, L-Alaninamide, 3,4-difluoro-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(2-thienyl)- **316152-41-7P**, Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(3-thiazolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- **316152-43-9P**, Cyclohexanepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-, (.alpha.S)- **316152-45-1P**, L-Homoserinamide, N-[[[1-[(2,6-


dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-O-methyl-  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibition of growth or metastasis of cancer by administering indole peptidomimetics PAR-1 antagonists and combined with PAR-2 antagonists and other agents in relation to immunostimulant activity)

RN 252889-86-4 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 252889-87-5 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252889-88-6 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-

indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252889-89-7 CAPLUS

CN L-Methioninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-47-0 CAPLUS

CN L-Argininamide, O-methyl-N-[[[1-[(4-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-49-2 CAPLUS

CN L-Argininamide, N-[[[3-[(cyclopentylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316149-51-6 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316149-53-8 CAPLUS

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(3-phenylpropyl)-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316149-55-0 CAPLUS

CN L-Argininamide, N-[[[1-[(3-fluorophenyl)methyl]-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316149-57-2 CAPLUS

CN L-Argininamide, N-[[[1-[(2-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 316149-59-4 CAPLUS


CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(cyclohexylmethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316149-61-8 CAPLUS

CN L-Argininamide, O-methyl-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316149-63-0 CAPLUS


CN L-Argininamide, N-[[[1-[4-(methoxycarbonyl)phenyl]methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316149-65-2 CAPLUS  
 CN L-Argininamide, O-methyl-N-[[[3-(1-pyrrolidinylmethyl)-1-[[4-(trifluoromethoxy)phenyl]methyl]-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-67-4 CAPLUS

CN L-Argininamide, O-methyl-N-[[[1-[[4-(methylsulfonyl)phenyl]methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-69-6 CAPLUS

CN L-Argininamide, N-[[[1-[[4-(methylsulfonyl)phenyl]methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-71-0 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316149-73-2 CAPLUS


CN L-Argininamide, O-methyl-N-[[[1-(2-naphthalenylmethyl)-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316149-75-4 CAPLUS

CN L-Argininamide, N-[[[1-[(3-methoxyphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316149-77-6 CAPLUS

CN L-Argininamide, O-methyl-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-79-8 CAPLUS

CN L-Argininamide, O-methyl-N-[[[3-(1-pyrrolidinylmethyl)-1-[[4-(trifluoromethyl)phenyl]methyl]-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316149-81-2 CAPLUS

CN L-Argininamide, N-[[[1-[(4-chlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316149-83-4 CAPLUS

CN L-Argininamide, N-[[[1-[(4-methoxyphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316149-85-6 CAPLUS

CN L-Argininamide, N-[[[1-[(3,4-difluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-87-8 CAPLUS

CN L-Argininamide, O-methyl-N-[[[1-(phenylmethyl)-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-89-0 CAPLUS

CN L-Argininamide, N-[[[1-[(4-iodophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-91-4 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(4-pyridinyl)-L-alanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-93-6 CAPLUS

CN L-Argininamide, 3-cyclohexyl-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-alanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-95-8 CAPLUS

CN L-Argininamide, 4-fluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-97-0 CAPLUS

CN Benzenebutamide, N-[(1S)-4-[(aminoiminomethyl)amino]-1-[[[(phenylmethyl)amino]carbonyl]butyl]-.alpha.-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-99-2 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(2-thienyl)-L-alanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-01-3 CAPLUS


CN L-Argininamide, (2S)-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-2-phenylglycyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-03-5 CAPLUS  
 CN 2,3(1H)-Isoquinolinedicarboxamide, N3-[(1S)-4-[(aminoiminomethyl)amino]-1-[[[phenylmethyl]amino]carbonyl]butyl]-N2-[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]-3,4-dihydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316150-05-7 CAPLUS  
 CN L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(3-pyridinyl)-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-07-9 CAPLUS  
 CN L-Argininamide, N-[[[3-[[[3-(dimethylamino)propyl]methylamino]methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


NMe<sub>2</sub>

RN 316150-09-1 CAPLUS


CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-[[[3-(1-pyrrolidinyl)propyl]amino]methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316150-11-5 CAPLUS  
CN L-Argininamide, N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-2-propenyl-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 316150-13-7 CAPLUS  
 CN L-Argininamide, 4-amino-N-[[[3-[(diethylamino)methyl]-1-[(2-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-15-9 CAPLUS  
 CN L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316150-17-1 CAPLUS  
 CN L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(1-naphthalenyl)-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-19-3 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(2-naphthalenyl)-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-21-7 CAPLUS

CN L-Argininamide, 3-[1,1'-biphenyl]-4-yl-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-23-9 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(4-morpholinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-25-1 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[(dipropylamino)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-27-3 CAPLUS

CN L-Argininamide, O-ethyl-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-29-5 CAPLUS

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[(3-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-(1-methylethyl)-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-31-9 CAPLUS

CN L-Argininamide, N-[[[3-(1-azetidinylmethyl)-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-33-1 CAPLUS

CN L-Argininamide, N-[[[3-[(cyclopropylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-36-4 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-38-6 CAPLUS

CN L-Argininamide, 4-chloro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-40-0 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-4-nitro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-42-2 CAPLUS

CN L-Argininamide, 2,3,4,5,6-pentafluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-44-4 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-2-fluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-46-6 CAPLUS

CN L-Argininamide, 4-cyano-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316150-48-8 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(4-thiazolyl)-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-50-2 CAPLUS

CN L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(trifluoromethyl)-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-52-4 CAPLUS

CN L-Argininamide, N-[[[1-[(2-chlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-54-6 CAPLUS


CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-.beta.-phenyl-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316150-56-8 CAPLUS


CN L-Argininamide, 3,4-difluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-phenylethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316150-58-0 CAPLUS  
 CN L-Argininamide, N-[[[3-[(dibutylamino)methyl]-1-[(2-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 316150-60-4 CAPLUS  
 CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(4-fluorophenyl)methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316150-62-6 CAPLUS

CN L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-64-8 CAPLUS


CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 316150-66-0 CAPLUS  
 CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316150-68-2 CAPLUS


CN L-Argininamide, 4-bromo-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-70-6 CAPLUS  
 CN L-Argininamide, 3,4-difluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(2-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316150-72-8 CAPLUS  
 CN L-Argininamide, 3,4-difluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-75-1 CAPLUS  
 CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316150-77-3 CAPLUS

CN L-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N6-(1-methylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-79-5 CAPLUS


CN L-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-N6-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316150-81-9 CAPLUS


CN D-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-83-1 CAPLUS  
 CN D-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-85-3 CAPLUS  
 CN D-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N6-acetyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316150-87-5 CAPLUS  
 CN D-Histidinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-89-7 CAPLUS

CN L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-octyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-91-1 CAPLUS

CN L-Argininamide, N-[[[1-(cyclohexylmethyl)-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-93-3 CAPLUS

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-(3-phenylpropyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316150-95-5 CAPLUS

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[2-(4-fluorophenyl)ethyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-97-7 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N5-(aminocarbonyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-98-8 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]propyl]-4-chloro-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-00-5 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-3-amino-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-02-7 CAPLUS

CN L-Phenylalaninamide, N2-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-arginyl-3,4-difluoro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-04-9 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(5-aminopentyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-06-1 CAPLUS

CN L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316151-08-3 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(2R)-2-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-10-7 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,5-difluoro-D-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-12-9 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-4-iodo-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-14-1 CAPLUS

CN L-Argininamide, 2-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-16-3 CAPLUS

CN L-Argininamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[2-(methoxymethyl)-1-pyrrolidinyl]methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-18-5 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[(4-oxo-1-piperidinyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-20-9 CAPLUS

CN L-Argininamide, 3-fluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-naphthalenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-22-1 CAPLUS

CN L-Argininamide, N-[[[3-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]-1-(2-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-D-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NMe<sub>2</sub>

RN 316151-25-4 CAPLUS

CN L-Argininamide, N-[[[1-[(3,5-dichloro-4-pyridinyl)methyl]-3-[[[(2R)-2-(methoxymethyl)-1-pyrrolidinyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-27-6 CAPLUS


CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-[[4-(aminosulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 316151-30-1 CAPLUS  
 CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5-acetyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-32-3 CAPLUS  
 CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5-(1-iminoethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316151-34-5 CAPLUS  
 CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-36-7 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[(methyl-2-propenylamino)methyl]-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-38-9 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A



PAGE 1-B




RN 316151-40-3 CAPLUS


CN L-Ornithinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 316151-42-5 CAPLUS  
 CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5,N5-dimethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316151-44-7 CAPLUS  
 CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-3-amino-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-47-0 CAPLUS

CN L-Glutamamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-49-2 CAPLUS

CN L-Methioninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-51-6 CAPLUS

CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-53-8 CAPLUS

CN L-Phenylalaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-4-amino-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-55-0 CAPLUS

CN L-Argininamide, 1-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-prolyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-59-4 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-60-7 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-ethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-62-9 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-64-1 CAPLUS


CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316151-66-3 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-69-6 CAPLUS

CN Benzenepropanamide, N-[(1S)-4-amino-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-71-0 CAPLUS

CN Benzenepropanamide, N-[(1S)-4-amino-1-(1-piperidinyldicarbonyl)butyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316151-73-2 CAPLUS


CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 316151-75-4 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-


phenylalanyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316151-77-6 CAPLUS  
 CN Benzenepropanamide, .alpha.-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-N-[(1S)-3-[(1-iminoethyl)amino]-1-[[[(phenylmethyl)amino]carbonyl]propyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-79-8 CAPLUS

CN L-Ornithinamide, 4-chloro-N-[[[3-[(cyclopentylmethylamino)methyl]-1-[(2,6-dichlorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(2-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-81-2 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[[2-(dimethylamino)ethyl]amino]methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-83-4 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[[3-(dimethylamino)propyl]amino]methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-85-6 CAPLUS

CN L-Ornithinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[[1,3-dioxolan-2-ylmethyl]methylamino]methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-87-8 CAPLUS

CN L-Ornithinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-89-0 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[2-(1-methyl-1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-91-4 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-cyclopentyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-92-5 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-94-7 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-96-9 CAPLUS


CN Benzenebutanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-98-1 CAPLUS  
 CN 2-Naphthalenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316152-00-8 CAPLUS  
 CN 3-Pyridinepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316152-02-0 CAPLUS

CN 2-Thiophenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-04-2 CAPLUS

CN 4-Thiazolepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-06-4 CAPLUS

CN L-Phenylalaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-08-6 CAPLUS

CN L-Histidinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-10-0 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-11-1 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-13-3 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-thiazolyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-15-5 CAPLUS

CN L-Phenylalaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-17-7 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-[(1-iminoethyl)amino]ethyl]-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-19-9 CAPLUS

CN 2,5,8,11-Tetraazatridecanamide, N-[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]-3-[(3,4-difluorophenyl)methyl]-12-imino-6-[2-[(1-iminoethyl)amino]ethyl]-4,7-dioxo-, (3S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-20-2 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(1-pyrrolidin-1-yl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-21-3 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(1H-imidazol-1-yl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-23-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-4-amino-2-[[[(2S)-2-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3-(3,4-difluorophenyl)-1-oxopropyl]amino]-1-oxobutyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316152-25-7 CAPLUS  
 CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-28-0 CAPLUS  
 CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(2-aminoethyl)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-29-1 CAPLUS

CN L-Valinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-31-5 CAPLUS

CN L-Cysteinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-S-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316152-33-7 CAPLUS

CN L-Serinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-35-9 CAPLUS

CN L-Cysteinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-S-(triphenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-37-1 CAPLUS

CN D-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-39-3 CAPLUS

CN L-Alaninamide, 3,4-difluoro-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-41-7 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[ (phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(3-thiazolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-43-9 CAPLUS

CN Cyclohexanepropanamide, N-[(1S)-3-amino-1-[[ (phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-45-1 CAPLUS

CN L-Homoserinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **316152-47-3P**, Benzenepropanamide, N-[(1S)-3-amino-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- **316152-49-5P**, Benzenepropanamide, N-[(1S)-3-amino-1-[[[(4-nitrophenyl)methyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- **316152-51-9P**, Benzenepropanamide, N-[(1S)-3-amino-1-[[[(4-methyl-2-furanyl)methyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- **316152-53-1P**, Glycine, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-(2S)-2,4-diaminobutanoyl-2-phenyl-, methyl ester, (2S)- **316152-55-3P**, Benzenepropanamide, N-[(1S)-3-amino-1-[[[(1S)-2-hydroxy-1-phenylethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- **316152-57-5P**


, L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-5-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)-  
**316152-59-7P**, L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(3-thiazolidinylmethyl)-1H-indol-5-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- **316152-61-1P**, Benzenepropanamide,  
 N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-3,4-difluoro-.alpha.-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-5-yl]amino]carbonyl]amino]-, (.alpha.S)- **316152-63-3P**,  
 Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-4-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)-  
**316152-65-5P**, Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-4-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- **316152-67-7P**  
 , Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-7-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)-  
**316152-69-9P**, Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-3,4-difluoro-.alpha.-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-7-yl]amino]carbonyl]amino]-, (.alpha.S)- **316152-71-3P**,  
 L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-2-phenyl-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[(4-fluorophenyl)methyl]- **316152-73-5P**, L-Argininamide,  
 N-[[[2-chloro-1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-  
**316152-75-7P**, L-Argininamide, N-[[[2-chloro-1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-[(4-fluorophenyl)methyl]-  
**316152-77-9P**, L-Argininamide, O-methyl-N-[[[1-[(4-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-tyrosyl-N-(phenylmethyl)- **316152-79-1P**, L-Alaninamide,  
 N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)-  
**316152-81-5P**, D-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-3,4-difluoro-D-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- **316152-83-7P**, L-Alaninamide,  
 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)-  
**316152-85-9P**, D-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)-  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibition of growth or metastasis of cancer by administering indole peptidomimetics PAR-1 antagonists and combined with PAR-2 antagonists and other agents in relation to immunostimulant activity)

RN 316152-47-3 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-49-5 CAPLUS


CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(4-nitrophenyl)methyl]amino]carbo  
 nyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-  
 pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-,  
 (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 316152-51-9 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(4-methyl-2-furanyl)methyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-53-1 CAPLUS  
 CN Glycine, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-(2S)-2,4-diaminobutanoyl-2-phenyl-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316152-55-3 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(1S)-2-hydroxy-1-phenylethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-57-5 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-piperidin-1-ylmethyl)-1H-indol-5-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-59-7 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(3-thiazolidin-3-ylmethyl)-1H-indol-5-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316152-61-1 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-3,4-difluoro-α-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-5-yl]amino]carbonyl]amino]-, (.alpha.S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-63-3 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-4-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-65-5 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-4-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-67-7 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-7-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-69-9 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonylpropyl]-3,4-difluoro-.alpha.-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-7-yl]amino]carbonyl]amino]-, (.alpha.S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-71-3 CAPLUS


CN L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-2-phenyl-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316152-73-5 CAPLUS  
 CN L-Argininamide, N-[[[2-chloro-1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-75-7 CAPLUS


CN L-Argininamide, N-[[[2-chloro-1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316152-77-9 CAPLUS

CN L-Argininamide, O-methyl-N-[[1-[(4-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-tyrosyl-N-(phenylmethyl)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-79-1 CAPLUS

CN L-Alaninamide, N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-81-5 CAPLUS

CN D-Alaninamide, N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-3,4-difluoro-D-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-83-7 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-85-9 CAPLUS

CN D-Alaninamide, 4-chloro-N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 316152-99-5D, Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)-, resin-bound 444160-87-6 444160-88-7D, resin-bound

RL: RCT (Reactant); RACT (Reactant or reagent)


(inhibition of growth or metastasis of cancer by administering indole peptidomimetics PAR-1 antagonists and combined with PAR-2 antagonists and other agents in relation to immunostimulant activity)

RN 316152-99-5 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 444160-87-6 CAPLUS


CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 444160-88-7 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-1H-indol-6-

yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2  
 ACCESSION NUMBER: 2002:294231 CAPLUS  
 DOCUMENT NUMBER: 136:304058  
 TITLE: Method for reducing or preventing the establishment, growth or metastasis of cancer by administering PAR-1 and optionally PAR-2 antagonists  
 INVENTOR(S): D'andrea, Michael; Derian, Claudia; Woodrow, Hal Brent  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 603,229.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002045581	A1	20020418	US 2001-865869	20010525
US 6365617	B1	20020402	US 2000-603229	20000626
PRIORITY APPLN. INFO.:			US 1999-141555P	P 19990629
			US 2000-603229	A2 20000626

OTHER SOURCE(S): MARPAT 136:304058

ED Entered STN: 19 Apr 2002

AB We have discovered a method of modifying the tumor cell microenvironment to reduce or prevent the establishment, growth or metastasis of malignant cells comprising administering to a patient having malignant cells a pharmaceutically effective amt. of a PAR-1 inhibitor and optionally a PAR-2 inhibitor to prevent or reduce activation of normal cells within the tumor microenvironment. This method also has the effect in some patients of modulating the immune system to facilitate a more efficient immune response to malignant cells and maybe coupled with cytokine therapy and T-cell therapy to enhance the patient's immune response to the malignant cells.

IT 314752-00-6 314752-02-8 314752-03-9


314752-11-9 314752-12-0 314752-13-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method for reducing or preventing the establishment, growth or metastasis of cancer by administering PAR-1 and optionally PAR-2 antagonists)


RN 314752-00-6 CAPLUS  
 CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N2-(2-aminoethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 314752-02-8 CAPLUS  
 CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N2-(4-aminobutyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 314752-03-9 CAPLUS  
 CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N,N2-bis(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 314752-11-9 CAPLUS

CN L-Argininamide, N-(5-aminopentyl)-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]glycyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 314752-12-0 CAPLUS

CN L-Argininamide, N-[(4-chlorophenyl)methyl]-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]glycyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 314752-13-1 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-N-[(4-fluorophenyl)methyl]glycyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2001:12482 CAPLUS

DOCUMENT NUMBER: 134:71906

TITLE: Preparation of novel indole peptidomimetics as thrombin receptor antagonists

INVENTOR(S): Zhang, Han-cheng; Hoekstra, William J.; Maryanoff, Bruce E.; McComsey, David F.

PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA; Cor Therapeutics, Inc.

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000657	A2	20010104	WO 2000-US18018	20000629
WO 2001000657	A3	20010712		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,

LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,  
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2003224999 A1 20031204 US 2003-403542 20030331  
PRIORITY APPLN. INFO.: US 1999-141550P P 19990629  
US 2000-603231 A 20000626

OTHER SOURCE(S): MARPAT 134:71906  
ED Entered STN: 05 Jan 2001  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Indole derivs. I [A1 and A2 are certain D- or L-amino acid residues which may be substituted; R1 = amino, alkylamino, arylamino, heteroalkyl, etc.; R2 = H, halo, alkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, aryl, heteroaryl; R3, R4 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroalkyl, indanyl, etc. or R3R4N = (un)substituted piperidinyl, piperazinyl, morpholino, or pyrrolidinyl; R5 = (un)substituted aryl, arylalkyl, cycloalkyl, heteroaryl; R6 = H, alkyl; X = O, S; m = 0-3; n = 1 or 2; p = 0 or 1] were prepd. as thrombin receptor antagonists for the treatment of diseases assocd. with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, angiogenesis related disorders, cancer, and neurodegenerative disorders. Thus, compd. II, prepd. by a multistep procedure starting from 6-nitroindole (scheme given), showed IC50 = 0.28 and 0.47 .mu.M, resp., in the thrombin-induced gel-filtered platelet aggregation and thrombin receptor binding assays.

IT 252889-86-4P 252889-87-5P 252889-88-6P  
252889-89-7P 316149-47-0P 316149-49-2P  
316149-51-6P 316149-53-8P 316149-55-0P  
316149-57-2P 316149-59-4P 316149-61-8P  
316149-63-0P 316149-65-2P 316149-67-4P  
316149-69-6P 316149-71-0P 316149-73-2P  
316149-75-4P 316149-77-6P 316149-79-8P  
316149-81-2P 316149-83-4P 316149-85-6P  
316149-87-8P 316149-89-0P 316149-91-4P  
316149-93-6P 316149-95-8P 316149-97-0P  
316149-99-2P 316150-01-3P 316150-03-5P  
316150-05-7P 316150-07-9P 316150-09-1P  
316150-11-5P 316150-13-7P 316150-15-9P  
316150-17-1P 316150-19-3P 316150-21-7P  
316150-23-9P 316150-25-1P 316150-27-3P  
316150-29-5P 316150-31-9P 316150-33-1P  
316150-36-4P 316150-38-6P 316150-40-0P  
316150-42-2P 316150-44-4P 316150-46-6P  
316150-48-8P 316150-50-2P 316150-52-4P  
316150-54-6P 316150-56-8P 316150-58-0P  
316150-60-4P 316150-62-6P 316150-64-8P  
316150-66-0P 316150-68-2P 316150-70-6P  
316150-72-8P 316150-75-1P 316150-77-3P  
316150-79-5P 316150-81-9P 316150-83-1P  
316150-85-3P 316150-87-5P 316150-89-7P  
316150-91-1P 316150-93-3P 316150-95-5P  
316150-97-7P 316150-98-8P 316151-00-5P  
316151-02-7P 316151-04-9P 316151-06-1P  
316151-08-3P 316151-10-7P 316151-12-9P


316151-14-1P 316151-16-3P 316151-18-5P  
316151-20-9P 316151-22-1P 316151-25-4P  
316151-27-6P 316151-30-1P 316151-32-3P  
316151-34-5P 316151-36-7P 316151-38-9P  
316151-40-3P 316151-42-5P 316151-44-7P  
316151-47-0P 316151-49-2P 316151-51-6P  
316151-53-8P 316151-55-0P 316151-59-4P  
316151-60-7P 316151-62-9P 316151-64-1P  
316151-66-3P 316151-69-6P 316151-71-0P  
316151-73-2P 316151-75-4P 316151-77-6P  
316151-79-8P 316151-81-2P 316151-83-4P  
316151-85-6P 316151-87-8P 316151-89-0P  
316151-91-4P 316151-92-5P 316151-94-7P  
316151-96-9P 316151-98-1P 316152-00-8P  
316152-02-0P 316152-04-2P 316152-06-4P  
316152-08-6P 316152-10-0P 316152-11-1P  
316152-13-3P 316152-15-5P 316152-17-7P  
316152-19-9P 316152-20-2P 316152-21-3P  
316152-23-5P 316152-25-7P 316152-28-0P  
316152-29-1P 316152-31-5P 316152-33-7P  
316152-35-9P 316152-37-1P 316152-39-3P  
316152-41-7P 316152-43-9P 316152-45-1P  
316152-47-3P 316152-49-5P 316152-51-9P  
316152-53-1P 316152-55-3P 316152-57-5P  
316152-59-7P 316152-61-1P 316152-63-3P  
316152-65-5P 316152-67-7P 316152-69-9P  
316152-71-3P 316152-73-5P 316152-75-7P  
316152-77-9P 316152-79-1P 316152-81-5P  
316152-83-7P 316152-85-9P 316152-87-1P  
316153-13-6P 316153-15-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of novel indole peptidomimetics as thrombin receptor antagonists)

RN 252889-86-4 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 252889-87-5 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-

pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252889-88-6 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252889-89-7 CAPLUS

CN L-Methioninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316149-47-0 CAPLUS

CN L-Argininamide, O-methyl-N-[[[1-[(4-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-49-2 CAPLUS

CN L-Argininamide, N-[[[3-[(cyclopentylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-51-6 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(3-phenylpropyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316149-53-8 CAPLUS

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(3-phenylpropyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316149-55-0 CAPLUS

CN L-Argininamide, N-[[[1-[(3-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316149-57-2 CAPLUS

CN L-Argininamide, N-[[[1-[(2-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 316149-59-4 CAPLUS


CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(cyclohexylmethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 316149-61-8 CAPLUS

CN L-Argininamide, O-methyl-N-[[[1-[(3-methylphenyl)methyl]-3-(1-

pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316149-63-0 CAPLUS


CN L-Argininamide, N-[[[1-[[4-(methoxycarbonyl)phenyl]methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316149-65-2 CAPLUS

CN L-Argininamide, O-methyl-N-[[[3-(1-pyrrolidinylmethyl)-1-[[4-(trifluoromethoxy)phenyl]methyl]-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-67-4 CAPLUS

CN L-Argininamide, O-methyl-N-[[[1-[[4-(methylsulfonyl)phenyl]methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-69-6 CAPLUS

CN L-Argininamide, N-[[[1-[(4-cyanophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-71-0 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316149-73-2 CAPLUS


CN L-Argininamide, O-methyl-N-[[[1-(2-naphthalenylmethyl)-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 316149-75-4 CAPLUS

CN L-Argininamide, N-[[[1-[(3-methoxyphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316149-77-6 CAPLUS

CN L-Argininamide, O-methyl-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-79-8 CAPLUS

CN L-Argininamide, O-methyl-N-[[[3-(1-pyrrolidinylmethyl)-1-[[4-(trifluoromethyl)phenyl]methyl]-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-81-2 CAPLUS

CN L-Argininamide, N-[[[1-[4-chlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316149-83-4 CAPLUS

CN L-Argininamide, N-[[[1-[4-methoxyphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316149-85-6 CAPLUS

CN L-Argininamide, N-[[[1-[(3,4-difluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-87-8 CAPLUS

CN L-Argininamide, O-methyl-N-[[[1-(phenylmethyl)-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-89-0 CAPLUS

CN L-Argininamide, N-[[[1-[(4-iodophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-91-4 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(4-pyridinyl)-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-93-6 CAPLUS

CN L-Argininamide, 3-cyclohexyl-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-95-8 CAPLUS

CN L-Argininamide, 4-fluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-97-0 CAPLUS

CN Benzenebutanamide, N-[(1S)-4-[(aminoiminomethyl)amino]-1-[[[(phenylmethyl)amino]carbonyl]butyl]-.alpha.-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-99-2 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(2-thienyl)-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-01-3 CAPLUS

CN L-Argininamide, (2S)-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-2-phenylglycyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-03-5 CAPLUS

CN 2,3(1H)-Isoquinolinedicarboxamide, N3-[(1S)-4-[(aminoiminomethyl)amino]-1-[[[(phenylmethyl)amino]carbonyl]butyl]-N2-[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]-3,4-dihydro-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-05-7 CAPLUS

CN L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(3-pyridinyl)-L-alanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-07-9 CAPLUS

CN L-Argininamide, N-[[[3-[[[3-(dimethylamino)propyl]methylamino]methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 1-B

 $\text{---NMe}_2$ 


RN 316150-09-1 CAPLUS  
CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-[[[3-(1-pyrrolidinyl)propyl]amino]methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316150-11-5 CAPLUS  
 CN L-Argininamide, N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-2-propenyl-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-13-7 CAPLUS

CN L-Argininamide, 4-amino-N-[[[3-[(diethylamino)methyl]-1-[(2-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-15-9 CAPLUS

CN L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-17-1 CAPLUS

CN L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(1-naphthalenyl)-L-alanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-19-3 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(2-naphthalenyl)-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-21-7 CAPLUS

CN L-Argininamide, 3-[1,1'-biphenyl]-4-yl-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-23-9 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(4-morpholinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-25-1 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[(dipropylamino)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-27-3 CAPLUS

CN L-Argininamide, O-ethyl-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-29-5 CAPLUS

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[(3-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-(1-methylethyl)-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-31-9 CAPLUS

CN L-Argininamide, N-[[[3-(1-azetidinylmethyl)-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-33-1 CAPLUS

CN L-Argininamide, N-[[[3-[(cyclopropylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-36-4 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-38-6 CAPLUS

CN L-Argininamide, 4-chloro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316150-40-0 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-4-nitro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-42-2 CAPLUS

CN L-Argininamide, 2,3,4,5,6-pentafluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-44-4 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-2-fluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-46-6 CAPLUS

CN L-Argininamide, 4-cyano-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-48-8 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(4-thiazolyl)-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-50-2 CAPLUS

CN L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(trifluoromethyl)-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-52-4 CAPLUS

CN L-Argininamide, N-[[[1-[(2-chlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-54-6 CAPLUS


CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-.beta.-phenyl-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316150-56-8 CAPLUS


CN L-Argininamide, 3,4-difluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316150-58-0 CAPLUS  
 CN L-Argininamide, N-[[[3-[(dibutylamino)methyl]-1-[(2-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 316150-60-4 CAPLUS  
 CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316150-62-6 CAPLUS

CN L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-64-8 CAPLUS


CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 316150-66-0 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(4-pyridinylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



RN 316150-68-2 CAPLUS  
 CN L-Argininamide, 4-bromo-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-70-6 CAPLUS

CN L-Argininamide, 3,4-difluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(2-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-72-8 CAPLUS

CN L-Argininamide, 3,4-difluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-75-1 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-77-3 CAPLUS

CN L-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N6-(1-methylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-79-5 CAPLUS


CN L-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-N6-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 316150-81-9 CAPLUS  
 CN D-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-83-1 CAPLUS  
 CN D-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-85-3 CAPLUS  
 CN D-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N6-acetyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316150-87-5 CAPLUS  
 CN D-Histidinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-89-7 CAPLUS

CN L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-piperidin-1-ylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-octyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-91-1 CAPLUS

CN L-Argininamide, N-[[[1-(cyclohexylmethyl)-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-93-3 CAPLUS

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-(3-phenylpropyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316150-95-5 CAPLUS

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[2-(4-fluorophenyl)ethyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-97-7 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N5-(aminocarbonyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-98-8 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-4-chloro-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316151-00-5 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-3-amino-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-02-7 CAPLUS

CN L-Phenylalaninamide, N2-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-arginyl-3,4-difluoro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-04-9 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(5-aminopentyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-06-1 CAPLUS

CN L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-08-3 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(2R)-2-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-10-7 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,5-difluoro-D-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-12-9 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-4-iodo-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-14-1 CAPLUS

CN L-Argininamide, 2-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-16-3 CAPLUS

CN L-Argininamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[ (2R)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-18-5 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[(4-oxo-1-piperidinyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-20-9 CAPLUS

CN L-Argininamide, 3-fluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-naphthalenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-22-1 CAPLUS

CN L-Argininamide, N-[[[3-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]-1-[(2-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-D-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

 $\text{NMe}_2$ 

RN 316151-25-4 CAPLUS

CN L-Argininamide, N-[[[1-[(3,5-dichloro-4-pyridinyl)methyl]-3-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-27-6 CAPLUS


CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-[[4-(aminosulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






RN 316151-30-1 CAPLUS  
 CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5-acetyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-32-3 CAPLUS  
 CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5-(1-iminoethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316151-34-5 CAPLUS  
 CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-36-7 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[(methyl-2-propenylamino)methyl]-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-38-9 CAPLUS


CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 316151-40-3 CAPLUS


CN L-Ornithinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 316151-42-5 CAPLUS  
CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5,N5-dimethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316151-44-7 CAPLUS  
CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-3-amino-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-47-0 CAPLUS

CN L-Glutamamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-49-2 CAPLUS

CN L-Methioninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-51-6 CAPLUS

CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-53-8 CAPLUS

CN L-Phenylalaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-4-amino-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-55-0 CAPLUS

CN L-Argininamide, 1-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-prolyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-59-4 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-60-7 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-ethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-62-9 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316151-64-1 CAPLUS


CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316151-66-3 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-69-6 CAPLUS

CN Benzenepropanamide, N-[(1S)-4-amino-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-71-0 CAPLUS

CN Benzenepropanamide, N-[(1S)-4-amino-1-(1-piperidinylcarbonyl)butyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-73-2 CAPLUS


CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 316151-75-4 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-


phenylalanyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316151-77-6 CAPLUS  
 CN Benzenepropanamide, .alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-N-[(1S)-3-[(1-iminoethyl)amino]-1-[[[(phenylmethyl)amino]carbonyl]propyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-79-8 CAPLUS

CN L-Ornithinamide, 4-chloro-N-[[[3-[(cyclopentylmethylamino)methyl]-1-[(2,6-dichlorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(2-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-81-2 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[[2-(dimethylamino)ethyl]amino]methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-83-4 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[[3-(dimethylamino)propyl]amino]methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-85-6 CAPLUS

CN L-Ornithinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[[1,3-dioxolan-2-ylmethyl)methylamino]methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-87-8 CAPLUS

CN L-Ornithinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-89-0 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[2-(1-methyl-1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-91-4 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-cyclopentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-92-5 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316151-94-7 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-96-9 CAPLUS

CN Benzenebutanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-98-1 CAPLUS

CN 2-Naphthalenepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-00-8 CAPLUS

CN 3-Pyridinepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-02-0 CAPLUS

CN 2-Thiophenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-04-2 CAPLUS

CN 4-Thiazolepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-06-4 CAPLUS

CN L-Phenylalaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-08-6 CAPLUS

CN L-Histidinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-10-0 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-11-1 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-13-3 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-thiazolyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-15-5 CAPLUS

CN L-Phenylalaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-17-7 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-[(1-iminoethyl)amino]ethyl]-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-19-9 CAPLUS

CN 2,5,8,11-Tetraazatridecanamide, N-[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]-3-[(3,4-difluorophenyl)methyl]-12-imino-6-[2-[(1-iminoethyl)amino]ethyl]-4,7-dioxo-, (3S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-20-2 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-21-3 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(1H-imidazol-1-yl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-23-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-4-amino-2-[[[(2S)-2-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3-(3,4-difluorophenyl)-1-oxopropyl]amino]-1-oxobutyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



RN 316152-25-7 CAPLUS  
 CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-28-0 CAPLUS  
 CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(2-aminoethyl)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-29-1 CAPLUS

CN L-Valinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-31-5 CAPLUS

CN L-Cysteinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-S-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-33-7 CAPLUS

CN L-Serinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-35-9 CAPLUS

CN L-Cysteinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-S-(triphenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-37-1 CAPLUS

CN D-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-39-3 CAPLUS

CN L-Alaninamide, 3,4-difluoro-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-41-7 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(3-thiazolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-43-9 CAPLUS

CN Cyclohexanepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-45-1 CAPLUS

CN L-Homoserinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-47-3 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-49-5 CAPLUS


CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(4-nitrophenyl)methyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 316152-51-9 CAPLUS  
CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(4-methyl-2-furanyl)methyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316152-53-1 CAPLUS  
CN Glycine, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-(2S)-2,4-diaminobutanoyl-2-phenyl-, methyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-55-3 CAPLUS  
CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(1S)-2-hydroxy-1-phenylethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316152-57-5 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-5-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-59-7 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(3-thiazolidinylmethyl)-1H-indol-5-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-61-1 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-3,4-difluoro-.alpha.-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-5-yl]amino]carbonyl]amino]-, (.alpha.S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-63-3 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-4-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-65-5 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-4-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-67-7 CAPLUS


CN Benzenepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-7-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316152-69-9 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-3,4-difluoro-.alpha.-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidin-1-yl)-1H-indol-7-yl]amino]carbonyl]amino]-, (.alpha.S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 316152-71-3 CAPLUS  
 CN L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-2-phenyl-3-(1-pyrrolidin-1-yl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316152-73-5 CAPLUS

CN L-Argininamide, N-[[[2-chloro-1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-75-7 CAPLUS


CN L-Argininamide, N-[[[2-chloro-1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316152-77-9 CAPLUS

CN L-Argininamide, O-methyl-N-[[1-[(4-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-79-1 CAPLUS

CN L-Alaninamide, N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-81-5 CAPLUS

CN D-Alaninamide, N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-3,4-difluoro-D-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-83-7 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 316152-85-9 CAPLUS  
 CN D-Alaninamide, 4-chloro-N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316152-87-1 CAPLUS  
 CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 316153-13-6 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 3 HCl

RN 316153-15-8 CAPLUS


CN Benzenepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 252889-88-6


CMF C41 H43 Cl2 F2 N7 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



IT 316152-99-5DP, resin-bound


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of novel indole peptidomimetics as thrombin receptor antagonists)

RN 316152-99-5 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2001:12414 CAPLUS

DOCUMENT NUMBER: 134:71904

TITLE: Preparation of indole and indazole urea-peptoids as thrombin receptor antagonists

INVENTOR(S): McComsey, David F.; Hoekstra, William J.; Maryanoff, Bruce E.; Zhang, Han-cheng

PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA; Cor Therapeutics, Inc.

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000576	A1	20010104	WO 2000-US18021	20000629
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6365617	B1	20020402	US 2000-603229	20000626
PRIORITY APPLN. INFO.:			US 1999-141555P	P 19990629
			US 2000-603229	A 20000626
OTHER SOURCE(S):	MARPAT 134:71904			
ED	Entered STN: 05 Jan 2001			
GI				



II

AB Indole and indazole urea-peptoid compds. I [R1 = amino, alkylamino, arylamino, heteroalkyl, etc.; R2 = (un)substituted aryl, arylalkyl, cycloalkyl, heteroaryl; R3 = H, alkyl; R4, R5 = H, alkyl, aminoalkyl, aryl, aralkyl, heteroaryl, cycloalkyl, etc.; R6, R7 = H, alkyl, aminoalkyl, aminocycloalkyl, aryl, heteroarylalkyl, etc.; R8 = H, alkyl, aminoalkyl, allyl, cycloalkyl, aryl, heteroaryl, etc.; X = CH, N; n = 0-3; m = 0 or 1; p = 1 or 2] were prepd. as thrombin receptor antagonists for the treatment of diseases assocd. with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, angiogenesis related disorders, cancer, and neurodegenerative disorders. Thus, compd. II, prepd. by a multistep procedure starting from 6-nitroindole (scheme given), showed IC50 = 1.3 and 0.5 M, resp., in the thrombin-induced gel-filtered platelet aggregation and thrombin receptor binding assays.


IT 314752-00-6P 314752-02-8P 314752-03-9P  
314752-11-9P 314752-12-0P 314752-13-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of indole and indazole urea-peptoids as thrombin receptor antagonists)

RN 314752-00-6 CAPLUS


CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N2-(2-aminoethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 314752-02-8 CAPLUS  
 CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N2-(4-aminobutyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 314752-03-9 CAPLUS  
 CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N,N2-bis(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 314752-11-9 CAPLUS

CN L-Argininamide, N-(5-aminopentyl)-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]glycyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 314752-12-0 CAPLUS


CN L-Argininamide, N-[(4-chlorophenyl)methyl]-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]glycyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 314752-13-1 CAPLUS  
 CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-N-[(4-fluorophenyl)methyl]glycyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 314752-18-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of indole and indazole urea-peptoids as thrombin receptor antagonists)  
 RN 314752-18-6 CAPLUS  
 CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-N-[(4-fluorophenyl)methyl]glycyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2001:192750 CAPLUS

DOCUMENT NUMBER: 134:335986

TITLE: Discovery and Optimization of a Novel Series of Thrombin Receptor (PAR-1) Antagonists: Potent, Selective Peptide Mimetics Based on Indole and Indazole Templates

AUTHOR(S): Zhang, Han-Cheng; Derian, Claudia K.; Andrade-Gordon, Patricia; Hoekstra, William J.; McComsey, David F.; White, Kimberly B.; Poulter, Brenda L.; Addo, Michael F.; Cheung, Wai-Man; Damiano, Bruce P.; Oksenberg, Donna; Reynolds, Elwood E.; Pandey, Anjali; Scarborough, Robert M.; Maryanoff, Bruce E.

CORPORATE SOURCE: Drug Discovery, The R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477, USA

SOURCE: Journal of Medicinal Chemistry (2001), 44(7), 1021-1024

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 22 Mar 2001

AB Coughlin and coworkers identified the first example of a thrombin receptor (protease-activated receptor-1, PAR-1), a member of the vast superfamily of seven-transmembrane, G-protein-coupled receptors. PAR-1 mediates most of the cellular actions of thrombin, such as platelet aggregation, cell proliferation, inflammatory responses, and neurodegeneration. Thus, this receptor is an attractive drug discovery target for the possible treatment of various disorders such as thrombosis, restenosis, atherosclerosis, inflammation, cancer metastasis, and stroke. Here we describe a second-generation indazole-based SFLLR peptide mimetics, an archetype of which is RWJ-58259 a potent, selective PAR-1 antagonist with an improved

in vivo cardiovascular safety profile, demonstrated in vivo antirestenotic activity in a rat balloon angioplasty model.


IT 252889-86-4P 252889-87-5P 252889-88-6P  
316149-49-2P 316149-71-0P 316150-66-0P  
337961-58-7P 337961-59-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of a novel series of peptide mimetics based on indole and indazole templates as thrombin receptor (PAR-1) antagonists)

RN 252889-86-4 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 252889-87-5 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252889-88-6 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-49-2 CAPLUS

CN L-Argininamide, N-[[[3-[(cyclopentylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-71-0 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-66-0 CAPLUS


CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 337961-58-7 CAPLUS  
 CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 337961-59-8 CAPLUS  
 CN L-Argininamide, O-methyl-N-[[[3-(1-pyrrolidinylmethyl)-1-[[4-(trifluoromethoxy)phenyl]methyl]-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 6  
 ACCESSION NUMBER: 1999:728849 CAPLUS  
 DOCUMENT NUMBER: 132:44502  
 TITLE: Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor  
 AUTHOR(S): Andrade-Gordon, Patricia; Maryanoff, Bruce E.; Derian, Claudia K.; Zhang, Han-Cheng; Addo, Michael F.; Darrow, Andrew L.; Eckardt, Annette J.; Hoekstra, William J.; McComsey, David F.; Oksenberg, Donna; Reynolds, Elwood E.; Santulli, Rosemary J.; Scarborough, Robert M.; Smith, Charles E.; White, Kimberly B.

CORPORATE SOURCE: Drug Discovery, The R. W. Johnson Pharmaceutical  
Research Institute, Spring House, PA, 19477, USA

SOURCE: Proceedings of the National Academy of Sciences of the  
United States of America (1999), 96(22), 12257-12262  
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 17 Nov 1999


AB Protease-activated receptors (PARs) represent a unique family of  
seven-transmembrane G protein-coupled receptors, which are enzymically  
cleaved to expose a truncated extracellular N terminus that acts as a  
tethered activating ligand. PAR-1 is cleaved and activated by the serine  
protease .alpha.-thrombin, is expressed in various tissues (e.g.,  
platelets and vascular cells), and is involved in cellular responses  
assocd. with hemostasis, proliferation, and tissue injury. We have  
discovered a series of potent peptide-mimetic antagonists of PAR-1,  
exemplified by RWJ-56110. Spatial relationships between important  
functional groups of the PAR-1 agonist peptide epitope SFLLRN were  
employed to design and synthesize candidate ligands with appropriate  
groups attached to a rigid mol. scaffold. Prototype RWJ-53052 was  
identified and optimized via solid-phase parallel synthesis of chem.  
libraries. RWJ-56110 emerged as a potent, selective PAR-1 antagonist,  
devoid of PAR-1 agonist and thrombin inhibitory activity. It binds to  
PAR-1, interferes with PAR-1 calcium mobilization and cellular function  
(platelet aggregation; cell proliferation), and has no effect on PAR-2,  
PAR-3, or PAR-4. By flow cytometry, RWJ-56110 was confirmed as a direct  
inhibitor of PAR-1 activation and internalization, without affecting  
N-terminal cleavage. At high concns. of .alpha.-thrombin, RWJ-56110 fully  
blocked activation responses in human vascular cells, albeit not in human  
platelets; whereas, at high concns. of SFLLRN-NH2, RWJ-56110 blocked  
activation responses in both cell types. Thus, thrombin activates human  
platelets independently of PAR-1, i.e., through PAR-4, which we confirmed  
by PCR anal. Selective PAR-1 antagonists, such as RWJ-56110, should serve  
as useful tools to study PARs and may have therapeutic potential for  
treating thrombosis and restenosis.

IT 252889-86-4P, RWJ 53052 252889-87-5P, RWJ 54399  
252889-88-6P, RWJ 56110 252889-89-7P, RWJ 57269  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); PNU (Preparation, unclassified); BIOL (Biological  
study); PREP (Preparation)  
(design, synthesis, and biol. characterization of peptidomimetic  
antagonists for protease-activated receptor PAR-1)

RN 252889-86-4 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-  
1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 252889-87-5 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252889-88-6 CAPLUS


CN Benzenepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252889-89-7 CAPLUS  
 CN L-Methioninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 2003:442763 CAPLUS  
 DOCUMENT NUMBER: 139:207078  
 TITLE: High-affinity thrombin receptor (PAR-1) ligands: a new generation of indole-based peptide mimetic antagonists with a basic amine at the C-terminus  
 AUTHOR(S): Zhang, Han-Cheng; White, Kimberly B.; McComsey, David F.; Addo, Michael F.; Andrade-Gordon, Patricia; Derian, Claudia K.; Oksenberg, Donna; Maryanoff, Bruce E.  
 CORPORATE SOURCE: Drug Discovery, Johnson & Johnson Pharmaceutical Research & Development, Spring House, PA, 19477-0776, USA  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(13), 2199-2203  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science B.V.




DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 139:207078  
 ED Entered STN: 10 Jun 2003  
 AB A new generation of indole-based peptidomimetics, bearing a basic amine at the C-terminus, was developed by the agency of two complementary, multistep, trityl resin-based approaches. Thus, we obtained several high-affinity thrombin receptor (PAR-1) ligands. These compds. were found to bind to PAR-1 with excellent affinity (IC50=25 and 35 nM, resp.) and to effectively block platelet aggregation induced by SFLLRN-NH2 (TRAP-6) and .alpha.-thrombin.  
 IT 252889-88-6P 252889-89-7P 316152-20-2P  
 316152-65-5P 587887-02-3P 587887-03-4P  
 587887-04-5P 587887-05-6P 587887-06-7P  
 587887-07-8P 587887-08-9P 587887-09-0P  
 587887-10-3P 587887-11-4P 587887-12-5P  
 587887-13-6P 587887-14-7P 587887-15-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (high-affinity thrombin receptor (PAR-1) ligands as platelet aggregation inhibitors)  
 RN 252889-88-6 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252889-89-7 CAPLUS  
 CN L-Methioninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-20-2 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316152-65-5 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-4-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 587887-02-3 CAPLUS


CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(4-methoxyphenyl)methyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 587887-03-4 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(2-phenylethyl)amino]carbonyl]propyl]-.alpha.-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 587887-04-5 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(2-furanylmethyl)amino]carbonyl]propyl]-.alpha.-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 587887-05-6 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-thienylmethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 587887-06-7 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-pyridinylmethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 587887-07-8 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(2-pyridinyl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 587887-08-9 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(ethylamino)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-,

(.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 587887-09-0 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-7-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 587887-10-3 CAPLUS


CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 587887-11-4 CAPLUS  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[3-aminopropyl]amino]carbonyl]propyl]-4-chloro-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 587887-12-5 CAPLUS  
 CN L-Histidinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 587887-13-6 CAPLUS

CN L-Cysteinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-S-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 587887-14-7 CAPLUS


CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-2-fluoro-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 587887-15-8 CAPLUS  
 CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 2003:262705 CAPLUS  
 DOCUMENT NUMBER: 139:127220  
 TITLE: Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1)  
 AUTHOR(S): Maryanoff, Bruce E.; Zhang, Han-Cheng; Andrade-Gordon, Patricia; Derian, Claudia K.  
 CORPORATE SOURCE: Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA, 19477-0776, USA  
 SOURCE: Current Medicinal Chemistry: Cardiovascular & Hematological Agents (2003), 1(1), 13-36  
 CODEN: CMCCDP; ISSN: 1568-0169  
 PUBLISHER: Bentham Science Publishers Ltd.  
 DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

ED Entered STN: 06 Apr 2003

AB A review. Protease-activated receptors (PARs) represent a unique family of seven-transmembrane G-protein-coupled receptors, which are enzymically cleaved to expose a new extracellular N-terminus that acts as a tethered activating ligand. PAR-1 is cleaved and activated by the serine protease .alpha.-thrombin, is expressed in various tissues (e.g., platelets and vascular cells), and is involved in cellular responses assocd. with hemostasis, proliferation, and tissue injury. By using a de novo design approach, we have discovered a series of potent heterocycle-based peptide-mimetic antagonists of PAR-1, exemplified by advanced leads RWJ-56110 and RWJ-58259. These compds. are potent, selective PAR-1 antagonists, devoid of PAR-1 agonist and thrombin inhibitory activity: they bind to PAR-1, interfere with calcium mobilization and cellular functions assocd. with PAR-1, and do not affect PAR-2, PAR-3, or PAR-4. RWJ-56110 was detd. to be a direct inhibitor of PAR-1 activation and internalization, without affecting PAR-1 N-terminal cleavage. At high concns. of .alpha.-thrombin, RWJ-56110 fully blocked activation responses in human vascular cells, but not in human platelets; whereas, at high concns. of TRAP-6, RWJ-56110 blocked activation responses in both cell types. This result is consistent with the presence of another thrombin receptor on human platelets, namely PAR-4. RWJ-56110 and RWJ-58259 clearly interrupt the binding of a tethered ligand to its receptor. RWJ-58259 demonstrated antirestenotic activity in a rat balloon angioplasty model and antithrombotic activity in a cynomolgus monkey arterial injury model. Such PAR-1 antagonists should not only serve as useful tools to delineate the physiol. and pathophysiol. roles of PAR-1, but also may have therapeutic potential for treating thrombosis and restenosis in humans.

IT 252889-88-6, RWJ-56110


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(discovery of potent peptide-mimetic antagonists for human thrombin receptor, protease-activated receptor-1 (PAR-1))

RN 252889-88-6 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

79

THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:612021 CAPLUS

DOCUMENT NUMBER: 136:548

TITLE: Thrombin receptor (PAR-1) antagonists. Solid-phase synthesis of indole-based peptide mimetics by anchoring to a secondary amide

AUTHOR(S): Zhang, H.-C.; McComsey, D. F.; White, K. B.; Addo, M. F.; Andrade-Gordon, P.; Derian, C. K.; Oksenberg, D.; Maryanoff, B. E.

CORPORATE SOURCE: Drug Discovery, The R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477-0776, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(16), 2105-2109

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 23 Aug 2001

AB A novel, 10-step, solid-phase method, based on a secondary amide linker, was developed to construct a diverse library of indole-based SFLLR peptide mimetics as thrombin receptor (protease-activated receptor 1, PAR-1) antagonists. The key steps include stepwise reductive alkylation, urea formation, and Mannich reaction. Screening of the library led to a quick development of the SAR and the significant improvement of PAR-1 activity.

IT 252889-86-4, RWJ-53052


RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(solid-phase synthesis of indole-based peptidomimetic thrombin receptor (PAR-1) antagonists by anchoring to a secondary amide and structure activity studies)

RN 252889-86-4 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



IT 252889-87-5P 252889-88-6P 316149-51-6P  
316149-59-4P 316149-65-2P 316149-71-0P  
316150-31-9P 316150-40-0P 316150-46-6P  
316150-75-1P 316151-44-7P 316151-47-0P  
316151-49-2P 375392-69-1P 375392-70-4P  
375392-71-5P 375392-72-6P 375392-73-7P


375392-74-8P 375392-75-9P 375392-76-0P  
 375392-77-1P 375392-78-2P 375392-79-3P  
 375392-80-6P 375392-81-7P 375392-82-8P  
 375392-83-9P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process) (solid-phase synthesis of indole-based peptidomimetic thrombin receptor (PAR-1) antagonists by anchoring to a secondary amide and structure activity studies)

RN 252889-87-5 CAPLUS

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252889-88-6 CAPLUS

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-51-6 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(3-phenylpropyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 316149-59-4 CAPLUS


CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(cyclohexylmethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316149-65-2 CAPLUS

CN L-Argininamide, O-methyl-N-[[[3-(1-pyrrolidinylmethyl)-1-[[4-(trifluoromethoxy)phenyl]methyl]-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-71-0 CAPLUS


CN L-Argininamide, N-[[[1-[[2,6-dichlorophenyl]methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-31-9 CAPLUS  
 CN L-Argininamide, N-[[[3-(1-azetidinylmethyl)-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316150-40-0 CAPLUS  
 CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-4-nitro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-46-6 CAPLUS  
 CN L-Argininamide, 4-cyano-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316150-75-1 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-44-7 CAPLUS

CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-3-amino-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-47-0 CAPLUS

CN L-Glutamamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-49-2 CAPLUS

CN L-Methioninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 375392-69-1 CAPLUS

CN L-Argininamide, N-[[[1-[(2-chlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(3-phenylpropyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 375392-70-4 CAPLUS

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[(3-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(3-phenylpropyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 375392-71-5 CAPLUS

CN L-Argininamide, O-methyl-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 375392-72-6 CAPLUS

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[(2-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 375392-73-7 CAPLUS

CN L-Argininamide, O-methyl-N-[[[1-[(2-methylphenyl)methyl]-3-(1-piperidin-4-ylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 375392-74-8 CAPLUS

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidin-2-ylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 375392-75-9 CAPLUS

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(cyclohexylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 375392-76-0 CAPLUS


CN L-Argininamide, O-methyl-N-[[[1-[(3-methylphenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(cyclohexylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 375392-77-1 CAPLUS

CN L-Argininamide, N-[[[1-[4-(methoxycarbonyl)phenyl]methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 375392-78-2 CAPLUS

CN L-Argininamide, O-methyl-N-[[[3-(1-piperidinylmethyl)-1-[[4-


(trifluoromethoxy)phenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN	375392-79-3	CAPLUS
CN	L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-4-nitro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)	

Absolute stereochemistry.






RN 375392-80-6 CAPLUS

CN L-Argininamide, 4-cyano-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 375392-81-7 CAPLUS

CN L-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 375392-82-8 CAPLUS

CN L-Histidinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 375392-83-9 CAPLUS

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5-(aminocarbonyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 10 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2003:319250 USPATFULL

TITLE: Novel indole peptidomimetics as thrombin receptor antagonists

INVENTOR(S): Zhang, Han-Cheng, Lansdale, PA, UNITED STATES  
Hoekstra, William J., Chapel Hill, NC, UNITED STATES  
Maryanoff, Bruce E., Forest Grove, PA, UNITED STATES  
McComsey, David F., Warminster, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003224999	A1	20031204
APPLICATION INFO.:	US 2003-403542	A1	20030331 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-603231, filed on 26 Jun 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-141550P	19990629 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2343	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to novel indole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indole peptidomimetics of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 252889-86-4P 252889-87-5P 252889-88-6P


252889-89-7P 316149-47-0P 316149-49-2P  
316149-51-6P 316149-53-8P 316149-55-0P  
316149-57-2P 316149-59-4P 316149-61-8P  
316149-63-0P 316149-65-2P 316149-67-4P  
316149-69-6P 316149-71-0P 316149-73-2P  
316149-75-4P 316149-77-6P 316149-79-8P  
316149-81-2P 316149-83-4P 316149-85-6P  
316149-87-8P 316149-89-0P 316149-91-4P  
316149-93-6P 316149-95-8P 316149-97-0P  
316149-99-2P 316150-01-3P 316150-03-5P  
316150-05-7P 316150-07-9P 316150-09-1P  
316150-11-5P 316150-13-7P 316150-15-9P  
316150-17-1P 316150-19-3P 316150-21-7P  
316150-23-9P 316150-25-1P 316150-27-3P  
316150-29-5P 316150-31-9P 316150-33-1P  
316150-36-4P 316150-38-6P 316150-40-0P  
316150-42-2P 316150-44-4P 316150-46-6P  
316150-48-8P 316150-50-2P 316150-52-4P  
316150-54-6P 316150-56-8P 316150-58-0P  
316150-60-4P 316150-62-6P 316150-64-8P  
316150-66-0P 316150-68-2P 316150-70-6P  
316150-72-8P 316150-75-1P 316150-77-3P  
316150-79-5P 316150-81-9P 316150-83-1P  
316150-85-3P 316150-87-5P 316150-89-7P  
316150-91-1P 316150-93-3P 316150-95-5P  
316150-97-7P 316150-98-8P 316151-00-5P  
316151-02-7P 316151-04-9P 316151-06-1P  
316151-08-3P 316151-10-7P 316151-12-9P  
316151-14-1P 316151-16-3P 316151-18-5P  
316151-20-9P 316151-22-1P 316151-25-4P  
316151-27-6P 316151-30-1P 316151-32-3P  
316151-34-5P 316151-36-7P 316151-38-9P  
316151-40-3P 316151-42-5P 316151-44-7P  
316151-47-0P 316151-49-2P 316151-51-6P  
316151-53-8P 316151-55-0P 316151-59-4P  
316151-60-7P 316151-62-9P 316151-64-1P  
316151-66-3P 316151-69-6P 316151-71-0P  
316151-73-2P 316151-75-4P 316151-77-6P  
316151-79-8P 316151-81-2P 316151-83-4P  
316151-85-6P 316151-87-8P 316151-89-0P  
316151-91-4P 316151-92-5P 316151-94-7P  
316151-96-9P 316151-98-1P 316152-00-8P  
316152-02-0P 316152-04-2P 316152-06-4P  
316152-08-6P 316152-10-0P 316152-11-1P  
316152-13-3P 316152-15-5P 316152-17-7P  
316152-19-9P 316152-20-2P 316152-21-3P  
316152-23-5P 316152-25-7P 316152-28-0P  
316152-29-1P 316152-31-5P 316152-33-7P  
316152-35-9P 316152-37-1P 316152-39-3P  
316152-41-7P 316152-43-9P 316152-45-1P  
316152-47-3P 316152-49-5P 316152-51-9P  
316152-53-1P 316152-55-3P 316152-57-5P  
316152-59-7P 316152-61-1P 316152-63-3P  
316152-65-5P 316152-67-7P 316152-69-9P  
316152-71-3P 316152-73-5P 316152-75-7P  
316152-77-9P 316152-79-1P 316152-81-5P  
316152-83-7P 316152-85-9P 316152-87-1P  
316153-13-6P 316153-15-8P

(prepn. of novel indole peptidomimetics as thrombin receptor  
antagonists)

RN 252889-86-4 USPATFULL  
CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-

1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 252889-87-5 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252889-88-6 USPATFULL

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 252889-89-7 USPATFULL

CN L-Methioninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-47-0 USPATFULL

CN L-Argininamide, O-methyl-N-[[[1-[(4-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-49-2 USPATFULL

CN L-Argininamide, N-[[[3-[(cyclopentylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-51-6 USPATFULL

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-53-8 USPATFULL

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(3-phenylpropyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316149-55-0 USPATFULL

CN L-Argininamide, N-[[[1-[(3-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316149-57-2 USPATFULL

CN L-Argininamide, N-[[[1-[(2-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 316149-59-4 USPATFULL


CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316149-61-8 USPATFULL

CN L-Argininamide, O-methyl-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316149-63-0 USPATFULL


CN L-Argininamide, N-[[[1-[[4-(methoxycarbonyl)phenyl]methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316149-65-2 USPATFULL  
CN L-Argininamide, O-methyl-N-[[[3-(1-pyrrolidinylmethyl)-1-[[4-(trifluoromethoxy)phenyl]methyl]-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-67-4 USPATFULL

CN L-Argininamide, O-methyl-N-[[[1-[[4-(methylsulfonyl)phenyl]methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-69-6 USPATFULL

CN L-Argininamide, N-[[[1-[[4-(cyanophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-71-0 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316149-73-2 USPATFULL


CN L-Argininamide, O-methyl-N-[[[1-(2-naphthalenylmethyl)-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316149-75-4 USPATFULL

CN L-Argininamide, N-[[[1-[(3-methoxyphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316149-77-6 USPATFULL

CN L-Argininamide, O-methyl-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-79-8 USPATFULL

CN L-Argininamide, O-methyl-N-[[[3-(1-pyrrolidinylmethyl)-1-[[4-(trifluoromethyl)phenyl]methyl]-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-81-2 USPATFULL

CN L-Argininamide, N-[[[1-[[4-(trifluoromethyl)phenyl]methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-83-4 USPATFULL

CN L-Argininamide, N-[[[1-[(4-methoxyphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 316149-85-6 USPATFULL

CN L-Argininamide, N-[[[1-[(3,4-difluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316149-87-8 USPATFULL

CN L-Argininamide, O-methyl-N-[[[1-(phenylmethyl)-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-89-0 USPATFULL

CN L-Argininamide, N-[[[1-[(4-iodophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-91-4 USPATFULL

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(4-pyridinyl)-L-alanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-93-6 USPATFULL

CN L-Argininamide, 3-cyclohexyl-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-alanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-95-8 USPATFULL

CN L-Argininamide, 4-fluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-97-0 USPATFULL

CN Benzenebutanamide, N-[(1S)-4-[(aminoiminomethyl)amino]-1-[[[(phenylmethyl)amino]carbonyl]butyl]-.alpha.-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316149-99-2 USPATFULL

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(2-thienyl)-L-alanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-01-3 USPATFULL


CN L-Argininamide, (2S)-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-2-phenylglycyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-03-5 USPATFULL  
CN 2,3(1H)-Isoquinolinedicarboxamide, N3-[(1S)-4-[(aminoiminomethyl)amino]-1-[[[(phenylmethyl)amino]carbonyl]butyl]-N2-[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]-3,4-dihydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316150-05-7 USPATFULL  
CN L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(3-pyridinyl)-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-07-9 USPATFULL  
CN L-Argininamide, N-[[[3-[[[3-(dimethylamino)propyl]methylamino]methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NMe<sub>2</sub>


RN 316150-09-1 USPATFULL  
CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-[[[3-(1-pyrrolidinyl)propyl]amino]methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 316150-11-5 USPATFULL  
 CN L-Argininamide, N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-2-propenyl-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-13-7 USPATFULL  
 CN L-Argininamide, 4-amino-N-[[[3-[(diethylamino)methyl]-1-[(2-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316150-15-9 USPATFULL  
 CN L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-17-1 USPATFULL  
 CN L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(1-naphthalenyl)-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316150-19-3 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(2-naphthalenyl)-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-21-7 USPATFULL

CN L-Argininamide, 3-[1,1'-biphenyl]-4-yl-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-23-9 USPATFULL

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(4-morpholinylmethyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316150-25-1 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-((dipropylamino)methyl)-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-27-3 USPATFULL

CN L-Argininamide, O-ethyl-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-29-5 USPATFULL

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[(3-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-(1-methylethyl)-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-31-9 USPATFULL

CN L-Argininamide, N-[[[3-(1-azetidinylmethyl)-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316150-33-1 USPATFULL

CN L-Argininamide, N-[[[3-[(cyclopropylamino)methyl]-1-[(4-fluorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-36-4 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-38-6 USPATFULL

CN L-Argininamide, 4-chloro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-40-0 USPATFULL

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-4-nitro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-42-2 USPATFULL

CN L-Argininamide, 2,3,4,5,6-pentafluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-44-4 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-2-fluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-46-6 USPATFULL

CN L-Argininamide, 4-cyano-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-48-8 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(4-thiazolyl)-L-alanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-50-2 USPATFULL

CN L-Argininamide, N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-(trifluoromethyl)-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316150-52-4 USPATFULL

CN L-Argininamide, N-[[[1-[(2-chlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-54-6 USPATFULL


CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-.beta.-phenyl-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316150-56-8 USPATFULL


CN L-Argininamide, 3,4-difluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-phenylethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316150-58-0 USPATFULL  
 CN L-Argininamide, N-[[[3-[(dibutylamino)methyl]-1-[(2-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 316150-60-4 USPATFULL  
 CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316150-62-6 USPATFULL

CN L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-64-8 USPATFULL


CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 316150-66-0 USPATFULL  
 CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316150-68-2 USPATFULL

CN L-Argininamide, 4-bromo-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-70-6 USPATFULL

CN L-Argininamide, 3,4-difluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(2-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-72-8 USPATFULL

CN L-Argininamide, 3,4-difluoro-N-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-75-1 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-77-3 USPATFULL

CN L-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N6-(1-methylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-79-5 USPATFULL

CN L-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-N6-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



RN 316150-81-9 USPATFULL


CN D-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-83-1 USPATFULL  
CN D-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316150-85-3 USPATFULL  
CN D-Lysinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N6-acetyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316150-87-5 USPATFULL  
CN D-Histidinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-89-7 USPATFULL

CN L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-octyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-91-1 USPATFULL

CN L-Argininamide, N-[[[1-(cyclohexylmethyl)-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-93-3 USPATFULL

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-(3-phenylpropyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-95-5 USPATFULL

CN L-Argininamide, N-[[[3-[(diethylamino)methyl]-1-[2-(4-fluorophenyl)ethyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-97-7 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N5-(aminocarbonyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316150-98-8 USPATFULL

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-4-chloro-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-00-5 USPATFULL

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-3-amino-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-02-7 USPATFULL

CN L-Phenylalaninamide, N2-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-arginyl-3,4-difluoro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-04-9 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(5-aminopentyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-06-1 USPATFULL

CN L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-08-3 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(2R)-2-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-10-7 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,5-difluoro-D-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316151-12-9 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-4-iodo-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-14-1 USPATFULL

CN L-Argininamide, 2-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-16-3 USPATFULL

CN L-Argininamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[ (2R)-2-(methoxymethyl)-1-pyrrolidinyl)methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-18-5 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[(4-oxo-1-piperidinyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-20-9 USPATFULL

CN L-Argininamide, 3-fluoro-N-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-22-1 USPATFULL

CN L-Argininamide, N-[[[3-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]-1-[(2-methylphenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-D-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NMe<sub>2</sub>

RN 316151-25-4 USPATFULL

CN L-Argininamide, N-[[[1-[(3,5-dichloro-4-pyridinyl)methyl]-3-[[2-(methoxymethyl)-1-pyrrolidinyl)methyl]-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-27-6 USPATFULL


CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-[[4-(aminosulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 316151-30-1 USPATFULL  
 CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5-acetyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-32-3 USPATFULL  
 CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5-(1-iminoethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316151-34-5 USPATFULL  
 CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-36-7 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[(methyl-2-propenylamino)methyl]-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-38-9 USPATFULL


CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316151-40-3 USPATFULL  
CN L-Ornithinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[(2-chlorophenyl)methyl]- (9Cl) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 1-B



RN 316151-42-5 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N5,N5-dimethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-44-7 USPATFULL

CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-3-amino-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-47-0 USPATFULL

CN L-Glutamamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-49-2 USPATFULL

CN L-Methioninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-51-6 USPATFULL

CN L-Alaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-53-8 USPATFULL

CN L-Phenylalaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-4-amino-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-55-0 USPATFULL

CN L-Argininamide, 1-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-prolyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-59-4 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-60-7 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-ethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-62-9 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-64-1 USPATFULL


CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316151-66-3 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-69-6 USPATFULL

CN Benzenepropanamide, N-[(1S)-4-amino-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-71-0 USPATFULL

CN Benzenepropanamide, N-[(1S)-4-amino-1-(1-piperidinylcarbonyl)butyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-73-2 USPATFULL


CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(3-pyridinylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 316151-75-4 USPATFULL


CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-




phenylalanyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316151-77-6 USPATFULL  
 CN Benzenepropanamide, .alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-N-[(1S)-3-[(1-iminoethyl)amino]-1-[[[phenylmethyl]amino]carbonyl]propyl]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-79-8 USPATFULL

CN L-Ornithinamide, 4-chloro-N-[[[3-[(cyclopentylmethylamino)methyl]-1-[(2,6-dichlorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(2-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-81-2 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[[2-(dimethylamino)ethyl]amino]methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-83-4 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[[3-(dimethylamino)propyl]amino]methyl]-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-85-6 USPATFULL

CN L-Ornithinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-[[[1,3-dioxolan-2-ylmethyl]methylamino]methyl]-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2,3-dihydro-1H-inden-2-yl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-87-8 USPATFULL

CN L-Ornithinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-89-0 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[2-(1-methyl-1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-91-4 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-cyclopentyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-92-5 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-94-7 USPATFULL

CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316151-96-9 USPATFULL


CN Benzenebutanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316151-98-1 USPATFULL  
 CN 2-Naphthalenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316152-00-8 USPATFULL  
 CN 3-Pyridinepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-02-0 USPATFULL

CN 2-Thiophenepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-04-2 USPATFULL

CN 4-Thiazolepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316152-06-4 USPATFULL

CN L-Phenylalaninamide, 4-chloro-N-[[[1-[ (2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-08-6 USPATFULL

CN L-Histidinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-10-0 USPATFULL

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-11-1 USPATFULL

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-13-3 USPATFULL

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-thiazolyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-15-5 USPATFULL

CN L-Phenylalaninamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-17-7 USPATFULL

CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[2-[(1-iminoethyl)amino]ethyl]-3-(4-pyridinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-19-9 USPATFULL

CN 2,5,8,11-Tetraazatridecanamide, N-[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]-3-[(3,4-difluorophenyl)methyl]-12-imino-6-[2-[(1-iminoethyl)amino]ethyl]-4,7-dioxo-, (3S,6S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-20-2 USPATFULL

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-21-3 USPATFULL

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(1H-imidazol-1-yl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-23-5 USPATFULL


CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-4-amino-2-[[[(2S)-2-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3-(3,4-difluorophenyl)-1-oxopropyl]amino]-1-oxobutyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 316152-25-7 USPATFULL  
CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 316152-28-0 USPATFULL  
CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-29-1 USPATFULL

CN L-Valinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-31-5 USPATFULL

CN L-Cysteinamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-S-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316152-33-7 USPATFULL

CN L-Serinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-35-9 USPATFULL

CN L-Cysteinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-S-(triphenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-37-1 USPATFULL

CN D-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-39-3 USPATFULL

CN L-Alaninamide, 3,4-difluoro-N-[[[1-[(3-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(3-aminopropyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-41-7 USPATFULL

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(3-thiazolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S) - (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316152-43-9 USPATFULL

CN Cyclohexanepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-, (.alpha.S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-45-1 USPATFULL

CN L-Homoserinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-47-3 USPATFULL

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-49-5 USPATFULL


CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(4-nitrophenyl)methyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316152-51-9 USPATFULL

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(4-methyl-2-furanyl)methyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-53-1 USPATFULL

CN Glycine, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-(2S)-2,4-diaminobutanoyl-2-phenyl-, methyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-55-3 USPATFULL

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(1S)-2-hydroxy-1-phenylethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-57-5 USPATFULL

CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(1-piperidinylmethyl)-1H-indol-5-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316152-59-7 USPATFULL


CN L-Argininamide, N-[[[1-[(4-fluorophenyl)methyl]-3-(3-thiazolidinylmethyl)-1H-indol-5-yl]amino]carbonyl]-O-methyl-L-tyrosyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 316152-61-1 USPATFULL  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-3,4-difluoro-.alpha.-[[[1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-5-yl]amino]carbonyl]amino]-, (.alpha.S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-63-3 USPATFULL  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-4-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 316152-65-5 USPATFULL

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-4-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-67-7 USPATFULL

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-7-yl]amino]carbonyl]-3,4-difluoro-, (.alpha.S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 316152-69-9 USPATFULL

CN Benzenepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl-3,4-difluoro-.alpha.-[[[1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-7-yl]amino]carbonyl]amino]-, (.alpha.S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-71-3 USPATFULL


CN L-Argininamide, 3,4-difluoro-N-[[[1-[(4-fluorophenyl)methyl]-2-phenyl-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316152-73-5 USPATFULL  
 CN L-Argininamide, N-[[[2-chloro-1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 316152-75-7 USPATFULL


CN L-Argininamide, N-[[[2-chloro-1-[(2-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3-fluoro-L-phenylalanyl-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 316152-77-9 USPATFULL

CN L-Argininamide, O-methyl-N-[[1-[(4-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-tyrosyl-N-(phenylmethyl)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-79-1 USPATFULL

CN L-Alaninamide, N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-  
1H-indol-6-yl]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-  
(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-81-5 USPATFULL

CN D-Alaninamide, N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-3,4-difluoro-D-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-83-7 USPATFULL

CN L-Alaninamide, 4-chloro-N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-85-9 USPATFULL

CN D-Alaninamide, 4-chloro-N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-87-1 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 316153-13-6 USPATFULL  
 CN L-Alaninamide, 4-chloro-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 3 HCl


RN 316153-15-8 USPATFULL  
 CN Benzenepropanamide, N-[(1S)-3-amino-1-[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 252889-88-6  
 CMF C41 H43 Cl2 F2 N7 O3




Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




IT 316152-99-5DP, resin-bound

(prepn. of novel indole peptidomimetics as thrombin receptor antagonists)

RN 316152-99-5 USPATFULL

CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 11 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2002:70009 USPATFULL

TITLE: Indole and indazole urea-peptoids as thrombin receptor antagonists

INVENTOR(S): McComsey, David F., Warminster, PA, United States  
Hoekstra, William J., Chapel Hill, NC, United States  
Maryanoff, Bruce E., Forest Grove, PA, United States  
Zhang, Han-Cheng, Lansdale, PA, United States

PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6365617	B1	20020402
APPLICATION INFO.:	US 2000-603229		20000626 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-141555P	19990629 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Ramsuer, Robert W.	
LEGAL REPRESENTATIVE:	Woodrow, Hal B.	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1177	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to novel indole and indazole urea-peptoid compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indole and indazole urea-peptoid compounds of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 314752-00-6P 314752-02-8P 314752-03-9P


314752-11-9P 314752-12-0P 314752-13-1P

(prepn. of indole and indazole urea-peptoids as thrombin receptor antagonists)

RN 314752-00-6 USPATFULL

CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N2-(2-aminoethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 314752-02-8 USPATFULL

CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N2-(4-aminobutyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 314752-03-9 USPATFULL

CN Glycinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-3,4-difluoro-L-phenylalanyl-N,N2-bis(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 314752-11-9 USPATFULL

CN L-Argininamide, N-(5-aminopentyl)-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]glycyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 314752-12-0 USPATFULL

CN L-Argininamide, N-[(4-chlorophenyl)methyl]-N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]glycyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 314752-13-1 USPATFULL

CN L-Argininamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]-N-[(4-fluorophenyl)methyl]glycyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 314752-18-6P


(prepn. of indole and indazole urea-peptoids as thrombin receptor antagonists)

RN 314752-18-6 USPATFULL


CN L-Ornithinamide, N-[[[1-[(2,6-dichlorophenyl)methyl]-1H-indol-6-yl]amino]carbonyl]-N-[(4-fluorophenyl)methyl]glycyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L16 ANSWER 12 OF 13 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN  
ACCESSION NUMBER: 2002:452697 BIOSIS  
DOCUMENT NUMBER: PREV200200452697  
TITLE: Characterization of thrombin-induced leukocyte rolling and  
adherence: A potential proinflammatory role for  
proteinase-activated receptor-4.  
AUTHOR(S): Vergnolle, Nathalie [Reprint author]; Derian, Claudia K.;  
D'Andrea, Michael R.; Steinhoff, Martin; Andrade-Gordon,  
Patricia  
CORPORATE SOURCE: Department of Pharmacology, Faculty of Medicine, University  
of Calgary, 3330 Hospital Drive NW, Calgary, AB, T2N4N1,  
Canada  
nvergnol@ucalgary.ca  
SOURCE: Journal of Immunology, (August 1, 2002) Vol. 169, No. 3,  
pp. 1467-1473. print.  
CODEN: JOIMA3. ISSN: 0022-1767.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 21 Aug 2002  
Last Updated on STN: 21 Aug 2002

ABSTRACT: It is commonly accepted that thrombin exerts its proinflammatory properties through the activation of proteinase-activated receptor (PAR)-1, although two other thrombin receptors have been discovered: PAR-3 and PAR-4. In this study, we have investigated the mechanisms and the receptors involved in thrombin-induced leukocyte/endothelial cell interactions by using selective agonists and antagonists of thrombin receptors in an in vivo intravital microscopy system. Topical addition of selective PAR-1 agonists to rat mesenteric venules failed to reproduce the increased leukocyte rolling and adhesion observed after thrombin topical addition. When added together with the selective PAR-1 antagonist RWJ-56110, thrombin was still able to provoke

increased leukocyte rolling and adherence. The thrombin-induced leukocyte rolling and adherence was not affected by pretreatment of rats with an anti-platelet serum. Selective PAR-4-activating peptide was able to reproduce the effects of thrombin on leukocyte rolling and adhesion. Intraperitoneal injection of PAR-4-activating peptide also caused a significant increase in leukocyte migration into the peritoneal cavity. In rat tissues, PAR-4 expression was detected both on endothelium and isolated leukocytes. Taken together, these results showed that in rat mesenteric venules, thrombin exerts proinflammatory properties inducing leukocyte rolling and adherence, by a mechanism independent of PAR-1 activation or platelet activation. However, PAR-4 activation either on endothelial cells or on leukocytes might be responsible for the thrombin-induced effects. These findings suggest that PAR-4 activation could contribute to several early events in the inflammatory reaction, including leukocyte rolling, adherence and recruitment, and that in addition to PAR-1, PAR-4 could be involved in proinflammatory properties of thrombin.

CONCEPT CODE: Cytology - General 02502  
Cytology - Animal 02506  
Biochemistry studies - General 10060  
Enzymes - Physiological studies 10808  
Blood - General and methods 15001  
Blood - Blood and lymph studies 15002  
Blood - Blood cell studies 15004  
Immunology - General and methods 34502

INDEX TERMS: Major Concepts  
Biochemistry and Molecular Biophysics; Cell Biology;  
Immune System (Chemical Coordination and Homeostasis)

INDEX TERMS: Parts, Structures, & Systems of Organisms  
leukocytes: blood and lymphatics, immune system

INDEX TERMS: Chemicals & Biochemicals  
RWJ-56110: proteinase-activated receptor-1 antagonist;  
proteinase-activated receptor-1; proteinase-activated  
receptor-3; proteinase-activated receptor-4; thrombin;  
thrombin receptors

INDEX TERMS: Miscellaneous Descriptors  
thrombin-induced leukocyte adherence: characterization;  
thrombin-induced leukocyte rolling: characterization;  
thrombin-induced leukocyte.endothelial cell interactions

ORGANISM: Classifier  
Muridae 86375  
Super Taxa  
Rodentia; Mammalia; Vertebrata; Chordata; Animalia  
Organism Name  
rat: strain-Wistar  
Taxa Notes  
Animals, Chordates, Mammals, Nonhuman Vertebrates,  
Nonhuman Mammals, Rodents, Vertebrates

REGISTRY NUMBER: 252889-88-6 (RWJ-56110)  
9002-04-4 (thrombin)

L16 ANSWER 13 OF 13 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN

ACCESSION NUMBER: 2000:15003 BIOSIS

DOCUMENT NUMBER: PREV200000015003

TITLE: A potent peptide-mimetic antagonist for the thrombin  
receptor (PAR1).

AUTHOR(S): Andrade-Gordon, Patricia [Reprint author]; Addo, Michael F.  
[Reprint author]; Darrow, Andrew L. [Reprint author];  
Derian, Claudia K.; Eckardt, Annette J.; Hoekstra, William  
J.; Maryanoff, Bruce E.; Oksenberg, Donna; Reynolds,  
Elwood; Santulli, Rosemary J.; Scarborough, Robert M.;  
Zhang, Han-Chen

CORPORATE SOURCE: R W Johnson Pharm Res Inst, Spring House, PA, USA  
SOURCE: Circulation, (Nov. 2, 1999) Vol. 100, No. 18 SUPPL., pp. I.471. print.  
Meeting Info.: 72nd Scientific Sessions of the American Heart Association. Atlanta, Georgia, USA. November 7-10, 1999.  
CODEN: CIRCAZ. ISSN: 0009-7322.

DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 29 Dec 1999  
Last Updated on STN: 31 Dec 2001

CONCEPT CODE: Cytology - Animal 02506  
Biochemistry studies - General 10060  
Blood - General and methods 15001  
General biology - Symposia, transactions and proceedings 00520

INDEX TERMS: Major Concepts  
Biochemistry and Molecular Biophysics; Cell Biology;  
Blood and Lymphatics (Transport and Circulation)

INDEX TERMS: Parts, Structures, & Systems of Organisms  
platelets: blood and lymphatics; protease-activated  
receptors, activation, functional characterization,  
structure-function relationship; vascular cells:  
circulatory system

INDEX TERMS: Chemicals & Biochemicals  
RWJ-56110: binding affinity, peptide-mimetic thrombin  
receptor antagonist, receptor specificity; SFLLRN:  
protease-activated receptor-1 antagonist; thrombin

INDEX TERMS: Miscellaneous Descriptors  
calcium mobilization; Meeting Abstract

ORGANISM: Classifier  
Animalia 33000  
Super Taxa  
Animalia  
Organism Name  
animal  
Taxa Notes  
Animals

REGISTRY NUMBER: 252889-88-6 (RWJ-56110)  
9002-04-4 (thrombin)

=> fil reg; s 252889-88-6  
FILE 'REGISTRY' ENTERED AT 14:37:58 ON 13 SEP 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 SEP 2004 HIGHEST RN 742663-39-4  
DICTIONARY FILE UPDATES: 10 SEP 2004 HIGHEST RN 742663-39-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.




Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L17 1 252889-88-6  
(252889-88-6/RN)

=> d ide l17

L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN  
RN **252889-88-6** REGISTRY  
CN Benzenepropanamide, N-[(1S)-3-amino-1-[[[(phenylmethyl)amino]carbonyl]propyl]-.alpha.-[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (.alpha.S)- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN RWJ 56110  
FS STEREOSEARCH  
MF C41 H43 Cl2 F2 N7 O3  
CI COM  
SR CA  
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, IMSRESEARCH, PHAR, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL  
DT.CA Caplus document type: Journal; Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)  
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

7 REFERENCES IN FILE CA (1907 TO DATE)  
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil cao; s l12

FILE 'CAOLD' ENTERED AT 14:38:15 ON 13 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L18 0 L12

=> fil hom  
FILE 'HOME' ENTERED AT 14:38:18 ON 13 SEP 2004